Oxidized hyaluronic acid cross-linked with adipic acid dihydrazide (oxi-HA/ADH) forms an injectable and biocompatible hydrogel suitable for treatment of musculoskeletal diseases and for drug delivery applications. In that sense, nanoporous silicon (nPSi) can be combined with biopolymers, such as oxi-HA/ADH hydrogel, to display new characteristics, which are not exhibited by the individual constituents alone. Under this context, in this work nPSi microparticles at concentrations from 0.1% to 1% m/v were embedded into oxi-HA/ADH hydrogel to improve its mechanical stability and enhance its control over drug release kinetics using Rose Bengal (RB) as a model drug because its cytotoxic effect in different cancer cell lines and tumors has been previously reported. Our results showed, for both compressive force and stress strength tests, that oxi-HA/ADH hydrogel with 1% nPSi microparticles doubled the values of control samples. Moreover, samples of oxi-HA/ADH with nPSi microparticles improved RB release kinetics control over pure oxi-HA/ADH hydrogel. Finally, the cell viability of nPSi microparticles embedded into oxi-HA/ADH hydrogel was confirmed using fibroblasts.

与己二酸二酰肼（oxi-HA / ADH）交联的氧化透明质酸形成可注射且生物相容的水凝胶，适用于治疗肌肉骨骼疾病和药物递送应用。从这个意义上讲，纳米多孔硅（nPSi）可以与生物聚合物（例如oxi-HA / ADH水凝胶）结合使用，以展现出新的特性，而单独的成分并不能展现出这些新特性。在这种情况下，在这项工作中，浓度为0.1％至1％m / v的nPSi微粒由于先前已经报道了其在不同癌细胞系和肿瘤中的细胞毒性作用，因此将其嵌入oxi-HA / ADH水凝胶以改善其机械稳定性并增强对药物释放动力学的控制（使用玫瑰孟加拉（RB）作为模型药物）。我们的结果表明，对于压缩力和应力强度测试，含1％nPSi微粒的oxi-HA / ADH水凝胶使对照样品的值翻倍。此外，与纯oxi-HA / ADH水凝胶相比，具有nPSi微粒的oxi-HA / ADH样品改善了RB释放动力学控制。最后，使用成纤维细胞证实了嵌入oxi-HA / ADH水凝胶的nPSi微粒的细胞活力。